预约演示

GSK concludes Aiolos Bio acquisition for $1.4bn

2024-02-16

交易

并购临床2期寡核苷酸

GSK’s respiratory portfolio focuses on therapies for diseases characterised by high eosinophil levels or high T2 inflammation. Credit: nitpicker / Shutterstock.com.

GSK has successfully concluded the acquisition of Aiolos Bio in a deal that could reach $1.4bn, marking ahigh T2 inflammationon of GSK’s respiratory biologics portfolio.

GSK agreement, signed last month, includes an upfrAiolos Biot of $1bn and $400m in regulatory milestone payments.GSK

The acquisition introduces AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, into GSK’s pipeline.

The antibody is ready to enAIO-001se II clinical development. It targets adults with asthma and has the potential forGSKtended dosing intervals, possibly every six months, due to its extended half-life and high potency.

AIO-001 operates by attaching to the TSLP ligand, a key player in asthma inflammationasthmainder its signalling pathway.

AIO-001o:GSK to license Elsie’s oligonucleotide discovery platformasthma inflammation

AbbVie coGSKudes acquisition of ImmunoGen for $10.1bn

The acquisition significantly benefits the estimated 40% of severe asthma patients who suffer from low Type 2 (T2) inflammation.

AbbViecommitment to respiratory ImmunoGenis further solidified with the addition of AIO-001, potentially redefining standard care for asthma patients.

The company’s respiratory portfolio focuses on therapies for diseases characterised by high eosinophil levels or high T2 inflammation.

The integration of AIO-001 into this portfolio could provide a new asthmaeutic option for patients with low T2 inflammation, a subset of the severe asthma population.

GSK will also make srespiratory diseasesne payments and tiered royalty payments to JAIO-001Hengrui Pharmaceuticals.asthma

Aiolos previously licensed development and marketing rights for AIO-001 from Hengrui for territories outside Greater Chininflammation

GSK chief scientifiAIO-001er Tony Wood stated: “Given the limited treatment options for asthma patients low T2 inflammationation, we look forward toasthma our deep respiratory expertise to potentially offer a long-acting biologic to a broader portion of the 315 million patients living with asthma.”

GSK latest development comes after the company received the China National Medical Jiangsu Hengrui Pharmaceuticalsl for Nucala (mepolizumab) as an add-on maintenance therapy for severe eosinophilic asthma in adults and adolescents aged 12 years and above.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构